GlassScriptPhysician profile
Roopa R Bhat
NPI 1699003871
$69,524.69
in general payments reported to CMS, 2019-2025
34 companies · $5,563 in 2025
The $5,563 reported for 2025 was more than what 86% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $26K · 2020: $14K · 2021: $6,629 · 2022: $2,912 · 2023: $1,297 · 2024: $13K · 2025: $5,563.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $16K · Food and Beverage: $3,476 · Education: $114 · Travel and Lodging: $32.78.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $16,300.00 |
| Food and Beverage | $3,475.53 |
| Education | $114.16 |
| Travel and Lodging | $32.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $17,130.98 | 2021-2025 | Botox |
| Celgene Corporation | $12,989.09 | 2019-2025 | Zeposia |
| Novartis Pharmaceuticals Corporation | $9,300.05 | 2019-2020 | |
| Emd Serono, INC. | $8,247.03 | 2019-2024 | Mavenclad |
| Mdd US Operations, LLC | $5,348.46 | 2019-2020 | |
| Biohaven Pharmaceuticals, INC. | $4,468.23 | 2020-2021 | |
| Teva Pharmaceuticals USA, INC. | $4,009.01 | 2019-2025 | Ajovy |
| Biohaven Pharmaceutical Holding Company LTD. | $2,514.19 | 2022 | |
| Biogen, INC. | $768.87 | 2019-2025 | Vumerity, Tysabri, Leqembi |
| Zyla Life Sciences, INC. | $553.08 | 2019-2020 | |
| Lilly USA, LLC | $377.05 | 2019-2020 | |
| Neurocrine Biosciences, INC. | $340.93 | 2019-2021 | |
| Pfizer INC. | $322.04 | 2023-2025 | |
| Genzyme Corporation | $282.87 | 2019-2024 | |
| Harmony Biosciences LLC | $254.74 | 2020-2022 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $248.38 | 2019 | |
| Argenx US, INC. | $241.86 | 2023-2025 | Vyvgart |
| Impel Pharmaceuticals INC. | $231.01 | 2023 | Trudhesa |
| Merz North America, INC. | $189.21 | 2024-2025 | |
| Allergan, INC. | $185.27 | 2019-2020 | |
| Novo Nordisk INC | $154.69 | 2023 | Wegovy |
| E.R. Squibb & Sons, L.L.C. | $151.82 | 2020-2022 | |
| Alexion Pharmaceuticals, INC. | $149.79 | 2019-2020 | |
| Upsher-Smith Laboratories LLC | $143.29 | 2019-2020 | |
| Supernus Pharmaceuticals, INC. | $136.76 | 2019 | |
| Amneal Pharmaceuticals LLC | $135.48 | 2019 | |
| Tg Therapeutics, INC. | $128.71 | 2024 | |
| Ipsen Biopharmaceuticals, INC | $125.00 | 2019 | |
| Kyowa Kirin, INC. | $121.86 | 2019 | |
| Acorda Therapeutics, INC | $99.73 | 2019 | |
| Assertio Therapeutics, INC. | $73.22 | 2020 | |
| Lundbeck LLC | $58.45 | 2021 | |
| Amgen INC. | $26.03 | 2020 | |
| Genentech USA, INC. | $17.51 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Roopa Bhat listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.